Saturday, 17 October 2026European Markets

AERKOMM INC Stock Over 26% Down In The Last 10 Sessions

Loading stream...

(vianews) - shares of aerkomm inc (cac 40: akom.pa) fell by a staggering 26.53% in 10 sessions from €2.94 to €2.16 at 02:42 est on monday, after five successive sessions in a row of losses. cac 40 is rising 1.34% to €7,388.65, following the last session's upward trend.

about aerkomm inc

aerkomm inc., together with its subsidiaries, focuses on providing in-flight entertainment and connectivity solutions in the asian pacific region. the company intends to offer airline passengers with broadband in-flight service options, such as wi-fi, cellular, movies, gaming, live tv, and music through built-in in-flight entertainment systems, such as seat-back displays, as well as on passengers' personal devices. it also focuses on providing content management services and e-commerce solutions; and aerkomm k++ system, a ifec system. the company is based in fremont, california.

earnings per share

as for profitability, aerkomm inc has a trailing twelve months eps of €-1.37.

more news about aerkomm inc (akom.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com